{"id":45934,"date":"2025-11-05T22:58:29","date_gmt":"2025-11-05T14:58:29","guid":{"rendered":"https:\/\/flcube.com\/?p=45934"},"modified":"2025-11-05T22:58:31","modified_gmt":"2025-11-05T14:58:31","slug":"dizal-highlights-breakthrough-findings-for-golidocitinib-and-birelentinib-at-ash-2025","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45934","title":{"rendered":"Dizal Highlights Breakthrough Findings for golidocitinib and birelentinib at ASH 2025"},"content":{"rendered":"\n<p><strong>Dizal Pharmaceutical Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/688192:SHA\">SHA: 688192<\/a>)<\/strong> announced that <em>multiple research updates<\/em> for its two core oncology assets\u2014<strong>golidocitinib<\/strong> and <strong>birelentinib (DZD8586)<\/strong>\u2014will be presented at the 67th <strong>American Society of Hematology (ASH) Annual Meeting<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-amp-meeting-context\">Company &amp; Meeting Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Dizal Pharmaceutical Co., Ltd. (SHA: 688192)<\/td><\/tr><tr><td><strong>Event<\/strong><\/td><td>67th ASH Annual Meeting, Nov\u202f5\u202f\u2013\u202f9\u202f,\u202f2025<\/td><\/tr><tr><td><strong>Products Discussed<\/strong><\/td><td>golidocitinib &amp; birelentinib (DZD8586)<\/td><\/tr><tr><td><strong>Previous US Milestone<\/strong><\/td><td>b\u2011relentininib Fast\u2011Track designation by the FDA (Aug\u202f2025)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-1-golidocitinib\">Product 1 \u2013 golidocitinib<\/h2>\n\n\n\n<p><strong>The first\u2011in\u2011world, JAK\/STAT\u2011pathway disruptor for Peripheral T\u2011cell Lymphoma (PTCL).<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Triple\u2011Mechanism Action<\/strong><\/li>\n\n\n\n<li><strong>Potent Tumor Suppression<\/strong><\/li>\n\n\n\n<li><strong>Anti\u2011Inflammatory Activity<\/strong><\/li>\n\n\n\n<li><strong>Immune\u2011Modulation<\/strong><\/li>\n\n\n\n<li><strong>Clinical Impact<\/strong><\/li>\n\n\n\n<li>Breaks the treatment bottleneck for <strong>relapsed\/refractory (r\/r) PTCL<\/strong>.<\/li>\n\n\n\n<li><strong>Longest median Overall Survival (mOS)<\/strong> among single\u2011agent r\/r\u202fPTCL therapies reported to date.<\/li>\n\n\n\n<li><strong>ASH 2025 Highlight<\/strong><\/li>\n\n\n\n<li>Latest Phase\u2011II data on mOS, tumor\u2011response rates, and safety will be presented in the Keynote session \u201cNovel Agents in T\u2011cell Lymphoma\u201d.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-2-birelentinib-dzd8586\">Product 2 \u2013 birelentinib (DZD8586)<\/h2>\n\n\n\n<p><strong>A global first\u2011in\u2011class, non\u2011covalent dual LYN\/BTK inhibitor that penetrates the blood\u2011brain barrier.<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Status<\/th><th>Indication<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase\u202fI\/II<\/strong><\/td><td>Ongoing<\/td><td>r\/r <em>Chronic Lymphocytic Leukemia \/ Small Lymphocytic Lymphoma<\/em> (CLL\/SLL) after BTK inhibitor or degrader exposure<\/td><\/tr><tr><td><strong>FDA Fast\u2011Track<\/strong><\/td><td>Granted (Aug\u202f2025)<\/td><td>r\/r CLL\/SLL<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Key ASH 2025 Data<\/strong><\/li>\n\n\n\n<li>Early safety and efficacy signals in heavily pre\u2011treated CLL\/SLL patients.<\/li>\n\n\n\n<li>Biomarker insights on BTK degrader resistance and blood\u2011brain barrier penetration.<\/li>\n\n\n\n<li><strong>Prior Conferences<\/strong><\/li>\n\n\n\n<li>Oral presentations at <strong>ASCO\u202f2025<\/strong> and <strong>ICML\u202f2025<\/strong> highlighted the drug\u2019s unique non\u2011covalent chemistry and CNS accessibility.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-amp-regulatory-significance\">Market &amp; Regulatory Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ASH 2025 Platform<\/strong> \u2013 A high\u2011profile venue that can accelerate global recognition and facilitate interactions with the worldwide hematology community.<\/li>\n\n\n\n<li><strong>Fast\u2011Track Status<\/strong> \u2013 Signals the FDA\u2019s recognition of the unmet need in r\/r\u202fCLL\/SLL, potentially shortening the U.S. approval timeline.<\/li>\n\n\n\n<li><strong>China\u2011US Parallel Track<\/strong> \u2013 Dizal\u2019s simultaneous pursuit of regulatory pathways in China and the U.S. positions the company to capture both domestic and international markets.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-bottom-line\">Bottom Line<\/h2>\n\n\n\n<p>Dizal\u2019s announcement underscores a dual\u2011product strategy:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>golidocitinib<\/strong>\u2014the only new\u2011mechanism JAK\/STAT inhibitor delivering the longest mOS in r\/r\u202fPTCL\u2014addresses an urgent unmet need in aggressive T\u2011cell disease.<\/li>\n\n\n\n<li><strong>birelentinib<\/strong>\u2014a first\u2011in\u2011class LYN\/BTK dual blocker with CNS penetration\u2014extends treatment options for heavily pre\u2011treated CLL\/SLL patients, bolstered by FDA Fast\u2011Track designation.<\/li>\n<\/ul>\n\n\n\n<p>The ASH 2025 disclosures are poised to further elevate Dizal\u2019s profile among clinicians, investors, and pay\u2011or\u2011perform\u2011in\u2011care buyers globally.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/688192_20251105_11WK.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688192_20251105_11WK.\"><\/object><a id=\"wp-block-file--media-21bc37d3-a78a-43a0-908c-2527e8ddfa47\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/688192_20251105_11WK.pdf\">688192_20251105_11WK<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/688192_20251105_11WK.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-21bc37d3-a78a-43a0-908c-2527e8ddfa47\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that multiple research updates for its two core&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45936,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,16,191,981,33],"class_list":["post-45934","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-academic-conference","tag-cancer","tag-dizal-pharmaceutical","tag-sha-688192","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Dizal Highlights Breakthrough Findings for golidocitinib and birelentinib at ASH 2025 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that multiple research updates for its two core oncology assets\u2014golidocitinib and birelentinib (DZD8586)\u2014will be presented at the 67th American Society of Hematology (ASH) Annual Meeting.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45934\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dizal Highlights Breakthrough Findings for golidocitinib and birelentinib at ASH 2025\" \/>\n<meta property=\"og:description\" content=\"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that multiple research updates for its two core oncology assets\u2014golidocitinib and birelentinib (DZD8586)\u2014will be presented at the 67th American Society of Hematology (ASH) Annual Meeting.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45934\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-05T14:58:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-05T14:58:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0509.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45934#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45934\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Dizal Highlights Breakthrough Findings for golidocitinib and birelentinib at ASH 2025\",\"datePublished\":\"2025-11-05T14:58:29+00:00\",\"dateModified\":\"2025-11-05T14:58:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45934\"},\"wordCount\":422,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45934#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0509.webp\",\"keywords\":[\"Academic conference\",\"Cancer\",\"Dizal Pharmaceutical\",\"SHA: 688192\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45934#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45934\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45934\",\"name\":\"Dizal Highlights Breakthrough Findings for golidocitinib and birelentinib at ASH 2025 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45934#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45934#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0509.webp\",\"datePublished\":\"2025-11-05T14:58:29+00:00\",\"dateModified\":\"2025-11-05T14:58:31+00:00\",\"description\":\"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that multiple research updates for its two core oncology assets\u2014golidocitinib and birelentinib (DZD8586)\u2014will be presented at the 67th American Society of Hematology (ASH) Annual Meeting.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45934#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45934\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45934#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0509.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0509.webp\",\"width\":1080,\"height\":608,\"caption\":\"Dizal Highlights Breakthrough Findings for golidocitinib and birelentinib at ASH 2025\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45934#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dizal Highlights Breakthrough Findings for golidocitinib and birelentinib at ASH 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Dizal Highlights Breakthrough Findings for golidocitinib and birelentinib at ASH 2025 - Insight, China&#039;s Pharmaceutical Industry","description":"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that multiple research updates for its two core oncology assets\u2014golidocitinib and birelentinib (DZD8586)\u2014will be presented at the 67th American Society of Hematology (ASH) Annual Meeting.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45934","og_locale":"en_US","og_type":"article","og_title":"Dizal Highlights Breakthrough Findings for golidocitinib and birelentinib at ASH 2025","og_description":"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that multiple research updates for its two core oncology assets\u2014golidocitinib and birelentinib (DZD8586)\u2014will be presented at the 67th American Society of Hematology (ASH) Annual Meeting.","og_url":"https:\/\/flcube.com\/?p=45934","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-05T14:58:29+00:00","article_modified_time":"2025-11-05T14:58:31+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0509.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45934#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45934"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Dizal Highlights Breakthrough Findings for golidocitinib and birelentinib at ASH 2025","datePublished":"2025-11-05T14:58:29+00:00","dateModified":"2025-11-05T14:58:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45934"},"wordCount":422,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45934#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0509.webp","keywords":["Academic conference","Cancer","Dizal Pharmaceutical","SHA: 688192","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45934#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45934","url":"https:\/\/flcube.com\/?p=45934","name":"Dizal Highlights Breakthrough Findings for golidocitinib and birelentinib at ASH 2025 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45934#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45934#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0509.webp","datePublished":"2025-11-05T14:58:29+00:00","dateModified":"2025-11-05T14:58:31+00:00","description":"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that multiple research updates for its two core oncology assets\u2014golidocitinib and birelentinib (DZD8586)\u2014will be presented at the 67th American Society of Hematology (ASH) Annual Meeting.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45934#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45934"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45934#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0509.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0509.webp","width":1080,"height":608,"caption":"Dizal Highlights Breakthrough Findings for golidocitinib and birelentinib at ASH 2025"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45934#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Dizal Highlights Breakthrough Findings for golidocitinib and birelentinib at ASH 2025"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0509.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45934","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45934"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45934\/revisions"}],"predecessor-version":[{"id":45938,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45934\/revisions\/45938"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45936"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45934"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45934"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45934"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}